Application Nr Approved Date Route Status External Links
NDA021332 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Symlin Is Indicated As An Adjunctive Treatment In Patients With Type 1 Or Type 2 Diabetes Who Use Mealtime Insulin Therapy And Who Have Failed To Achieve Desired Glucose Control Despite Optimal Insulin Therapy. Symlin Is An Amylin Analog Indicated For Patients With Type 1 Or Type 2 Diabetes Who Use Mealtime Insulin And Have Failed To Achieve Desired Glycemic Control Despite Optimal Insulin Therapy (1) .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Pramlintide Acetate

Comments